Edgar Filing: THERAVANCE INC - Form 4

THERAVA Form 4										
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									PPROVAL 3235-0287	
Check t if no lor subject Section Form 4 Form 5 obligati may con <i>See</i> Inst 1(b).	nger to 16. or Filed pu ons section 17	MENT OF ursuant to S (a) of the F 30(h)	Estimated burden hoi response	urs per						
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> WITEK THEODORE L JR			2. Issuer Name and Ticker or Trading Symbol THERAVANCE INC [THRX]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 951 GATEWAY BLVD.			3. Date of Earliest Transaction (Month/Day/Year) 07/24/2014				Director 10% Owner X Officer (give title Other (specify below) below) Sr. VP, Corp Partnerships			
SOUTH SA FRANCIS		4. If Amendment, Date Original Filed(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 				
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Data (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate lir	ne for each cla	ass of sec	urities bene	Perso inforr requi	ons who res nation cont red to resp	or indirectly. spond to the colle ained in this forr ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transact	iorDerivative	Expiration Date	Underlying Securities

number.

Edgar Filing: THERAVANCE INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Yea	Code ar) (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Year)		(Instr. 3 and 4)		
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option Grant (Right to Buy)	\$ 23.88	07/24/2014		А	125,000	<u>(1)</u>	07/23/2024	Common Stock	125,000	
Reporting Owners										
Repo	orting Owner Na	ame / Address	Director 10	0% Owner	Relationships Officer		Other			
	WITEK THEODORE L JR 951 GATEWAY BLVD.				Sr. VP, Corp Partnerships					

Signatures

Heather M. Shane,
Attorney-in-Fact07/28/2014

**Signature of Reporting Person

SOUTH SAN FRANCISCO, CA 94080

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

This option shall vest and become exercisable as follows: (a) with respect to the first 25% of the shares of the Company's Common Stock subject to the option when optionee completes 12 months of continuous service after the grant date and (b) with respect to an additional

(1) 1/48th of the shares of the Company's Common Stock subject to the option when optionee completes each month of continuous service thereafter. The option shall be fully vested and exercisable on the 4-year anniversary of the grant date provided optionee has remained in continuous service with the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.